FDA Prioritizes Review of Psychedelic Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: stocktwits
- Regulatory Push for Acceleration: President Trump signed an executive order aimed at expediting the development and review of psychedelic drugs, with the FDA prioritizing treatments that have shown positive results, thereby shortening regulatory timelines and expanding research opportunities.
- COMP360 Therapy Progress: Compass Pathways' COMP360 synthetic psilocybin has demonstrated rapid relief within a day for patients in late-stage trials, with effects lasting up to six months after just one or two doses, indicating its potential in treating depression.
- Positive Market Reaction: Compass Pathways' stock gained over 2% overnight on Sunday, reflecting market support for the White House's initiative to accelerate research and approval of psychedelic treatments, with peers like Enveric Biosciences and ATAI Life Sciences also seeing increases of over 3.5% and 1.1%, respectively.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for Compass Pathways remains in 'extremely bullish' territory, with message volume surging by 2,000% over the past week, indicating strong investor optimism regarding COMP360's potential FDA approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.590
Low
8.00
Averages
18.43
High
40.00
Current: 11.590
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Leadership Change Boosts Psychedelic Drug Prospects
- FDA Leadership Change: Michael Davis has been appointed as the acting head of the FDA's Center for Drug Evaluation and Research, previously serving as chief medical officer at Usona Institute, where he advanced psychedelic therapies, indicating a strong FDA focus on the psychedelic sector.
- COMP360 Receives Priority Voucher: Compass Pathways' synthetic psilocybin treatment, COMP360, has been granted a Commissioner’s National Priority Voucher by the FDA, which provides enhanced regulatory access and a significantly faster review timeline for treatment-resistant depression, greatly enhancing its market competitiveness.
- Stock Price Surge: Shares of Compass Pathways soared 16% in pre-market trading on Monday, and if these levels hold after the opening bell, the stock would reach its highest point in over two years, reflecting a resurgence of investor enthusiasm for psychedelic therapies.
- Investor Sentiment Optimistic: Retail sentiment on Stocktwits remains bullish for CMPS, with Jefferies forecasting a 75%-85% chance of FDA approval for COMP360 in FY26, further driving market interest and investment in the stock.
See More
Trump's Executive Order Accelerates Psychedelic Drug Development
- Investor Capital Influx: Trump's executive order has sparked interest among investors in psychedelic drug development companies, with Enveric Biosciences raising $5 million following the announcement, indicating heightened market attention despite researchers cautioning that new treatments are still far from realization.
- Improved FDA-DEA Coordination: Nine executives and investors noted that the order could shorten administrative timelines and enhance coordination between the FDA and DEA, potentially saving clinical-stage companies tens of millions in costs and improving overall research efficiency.
- Reduced Regulatory Uncertainty: Sa'ad Shah, co-founder of Noetic Fund, highlighted that the executive order may attract institutional investors like sovereign wealth funds and public pension plans into the psychedelic sector, alleviating previous regulatory uncertainties and signaling credible government backing for the industry.
- Accelerated Development Processes: Robert Barrow, CEO of Definium Therapeutics, stated that the implementation of the order will streamline regulatory processes, particularly allowing the DEA to begin scheduling controlled substances after FDA approval, which will facilitate faster market access for psychedelic drugs.
See More
Compass Pathways to Attend RBC Healthcare Conference
- Conference Participation: Compass Pathways plc will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026, participating in a fireside chat on May 19 at 10:00 am ET, showcasing its innovations in mental health.
- Live Webcast: The event will feature a live audio webcast accessible from the 'Events' page in the Investors section of the Compass website, ensuring investors can stay updated in real-time, enhancing transparency and investor confidence.
- Therapeutic Innovation: Compass Pathways is pioneering a new paradigm in mental health treatment through its investigational COMP360 synthetic psilocybin therapy, which has received Breakthrough Therapy designation from the FDA, indicating its potential in treating treatment-resistant depression.
- Global Presence: Headquartered in London, UK, with an office in New York, the company demonstrates a global strategy aimed at accelerating patient access to evidence-based mental health innovations, addressing the needs of patients not helped by existing treatments.
See More
COMPASS Pathways Q1 2026 Earnings Call Insights
- Regulatory Progress Accelerated: COMPASS Pathways confirmed a rolling NDA submission and received a National Priority Voucher in Q1, indicating readiness for launch by year-end, showcasing strong advancements in treatment-resistant depression.
- Clinical Data Highlights: CEO Nath emphasized COMP360's unique advantages of rapid onset and durable efficacy, which no other approved TRD drug offers, potentially enhancing the company's competitive edge in the market.
- FDA Review Timeline Expectations: The awarded National Priority Voucher could shorten the FDA review timeline to 1-2 months, with CCO Englebert noting that nearly 90% of the U.S. population lives in states planning to reschedule COMP360 within 30 days post-approval, further driving launch readiness.
- Strong Financial Position: While specific financial figures were not disclosed, Nath stated that successful financing and warrant exercises have resulted in a robust balance sheet, with cash projected to last well into 2028, ensuring operational stability for the future.
See More
COMPASS Pathways Q1 2026 Earnings Beat Expectations
- Earnings Highlights: COMPASS Pathways reported a Q1 GAAP EPS of -$0.30, beating expectations by $0.15, indicating a positive trend in financial performance despite ongoing losses.
- Cash Position: As of March 31, 2026, the company had $466.0 million in cash and cash equivalents, a significant increase from $149.6 million as of December 31, 2025, demonstrating substantial progress in cash management.
- Debt Increase: The company's debt stood at $50.5 million as of March 31, 2026, up from $31.6 million as of December 31, 2025, reflecting increased financing needs as the company expands its operations.
- Financial Guidance: COMPASS expects its current cash position to be sufficient to fund operating expenses and capital expenditures through 2028, showcasing confidence in its future stability and growth prospects.
See More
Compass Pathways Secures FDA NDA Rolling Review Approval
- Regulatory Acceleration: The FDA has granted Compass a rolling submission and review request for its NDA based on positive Phase 3 data for COMP360, with the final submission on track for Q4 2026, thereby expediting the drug's market entry for treatment-resistant depression.
- Strong Financial Position: Compass reported cash and cash equivalents of $466 million as of Q1 2026, a significant increase from $149.6 million at the end of 2025, ensuring sufficient funding for operations and supporting its commercialization efforts well into 2028.
- Promising Clinical Data: COMP360 has demonstrated significant clinical effects in three large late-stage trials, with 26-week Part B data expected to be released in early Q3 2026, which will further enhance market anticipation and confidence in the drug's efficacy.
- Commercial Readiness: Compass has assembled a highly experienced commercial leadership team and is advancing comprehensive launch preparedness efforts, including education initiatives with key opinion leaders and healthcare providers, ensuring that COMP360 can successfully meet market demands upon launch.
See More
FDA Leadership Change Boosts Psychedelic Drug Prospects
- FDA Leadership Change: Michael Davis has been appointed as the acting head of the FDA's Center for Drug Evaluation and Research, previously serving as chief medical officer at Usona Institute, where he advanced psychedelic therapies, indicating a strong FDA focus on the psychedelic sector.
- COMP360 Receives Priority Voucher: Compass Pathways' synthetic psilocybin treatment, COMP360, has been granted a Commissioner’s National Priority Voucher by the FDA, which provides enhanced regulatory access and a significantly faster review timeline for treatment-resistant depression, greatly enhancing its market competitiveness.
- Stock Price Surge: Shares of Compass Pathways soared 16% in pre-market trading on Monday, and if these levels hold after the opening bell, the stock would reach its highest point in over two years, reflecting a resurgence of investor enthusiasm for psychedelic therapies.
- Investor Sentiment Optimistic: Retail sentiment on Stocktwits remains bullish for CMPS, with Jefferies forecasting a 75%-85% chance of FDA approval for COMP360 in FY26, further driving market interest and investment in the stock.
See More
Trump's Executive Order Accelerates Psychedelic Drug Development
- Investor Capital Influx: Trump's executive order has sparked interest among investors in psychedelic drug development companies, with Enveric Biosciences raising $5 million following the announcement, indicating heightened market attention despite researchers cautioning that new treatments are still far from realization.
- Improved FDA-DEA Coordination: Nine executives and investors noted that the order could shorten administrative timelines and enhance coordination between the FDA and DEA, potentially saving clinical-stage companies tens of millions in costs and improving overall research efficiency.
- Reduced Regulatory Uncertainty: Sa'ad Shah, co-founder of Noetic Fund, highlighted that the executive order may attract institutional investors like sovereign wealth funds and public pension plans into the psychedelic sector, alleviating previous regulatory uncertainties and signaling credible government backing for the industry.
- Accelerated Development Processes: Robert Barrow, CEO of Definium Therapeutics, stated that the implementation of the order will streamline regulatory processes, particularly allowing the DEA to begin scheduling controlled substances after FDA approval, which will facilitate faster market access for psychedelic drugs.
See More
Compass Pathways to Attend RBC Healthcare Conference
- Conference Participation: Compass Pathways plc will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026, participating in a fireside chat on May 19 at 10:00 am ET, showcasing its innovations in mental health.
- Live Webcast: The event will feature a live audio webcast accessible from the 'Events' page in the Investors section of the Compass website, ensuring investors can stay updated in real-time, enhancing transparency and investor confidence.
- Therapeutic Innovation: Compass Pathways is pioneering a new paradigm in mental health treatment through its investigational COMP360 synthetic psilocybin therapy, which has received Breakthrough Therapy designation from the FDA, indicating its potential in treating treatment-resistant depression.
- Global Presence: Headquartered in London, UK, with an office in New York, the company demonstrates a global strategy aimed at accelerating patient access to evidence-based mental health innovations, addressing the needs of patients not helped by existing treatments.
See More
COMPASS Pathways Q1 2026 Earnings Call Insights
- Regulatory Progress Accelerated: COMPASS Pathways confirmed a rolling NDA submission and received a National Priority Voucher in Q1, indicating readiness for launch by year-end, showcasing strong advancements in treatment-resistant depression.
- Clinical Data Highlights: CEO Nath emphasized COMP360's unique advantages of rapid onset and durable efficacy, which no other approved TRD drug offers, potentially enhancing the company's competitive edge in the market.
- FDA Review Timeline Expectations: The awarded National Priority Voucher could shorten the FDA review timeline to 1-2 months, with CCO Englebert noting that nearly 90% of the U.S. population lives in states planning to reschedule COMP360 within 30 days post-approval, further driving launch readiness.
- Strong Financial Position: While specific financial figures were not disclosed, Nath stated that successful financing and warrant exercises have resulted in a robust balance sheet, with cash projected to last well into 2028, ensuring operational stability for the future.
See More
COMPASS Pathways Q1 2026 Earnings Beat Expectations
- Earnings Highlights: COMPASS Pathways reported a Q1 GAAP EPS of -$0.30, beating expectations by $0.15, indicating a positive trend in financial performance despite ongoing losses.
- Cash Position: As of March 31, 2026, the company had $466.0 million in cash and cash equivalents, a significant increase from $149.6 million as of December 31, 2025, demonstrating substantial progress in cash management.
- Debt Increase: The company's debt stood at $50.5 million as of March 31, 2026, up from $31.6 million as of December 31, 2025, reflecting increased financing needs as the company expands its operations.
- Financial Guidance: COMPASS expects its current cash position to be sufficient to fund operating expenses and capital expenditures through 2028, showcasing confidence in its future stability and growth prospects.
See More
Compass Pathways Secures FDA NDA Rolling Review Approval
- Regulatory Acceleration: The FDA has granted Compass a rolling submission and review request for its NDA based on positive Phase 3 data for COMP360, with the final submission on track for Q4 2026, thereby expediting the drug's market entry for treatment-resistant depression.
- Strong Financial Position: Compass reported cash and cash equivalents of $466 million as of Q1 2026, a significant increase from $149.6 million at the end of 2025, ensuring sufficient funding for operations and supporting its commercialization efforts well into 2028.
- Promising Clinical Data: COMP360 has demonstrated significant clinical effects in three large late-stage trials, with 26-week Part B data expected to be released in early Q3 2026, which will further enhance market anticipation and confidence in the drug's efficacy.
- Commercial Readiness: Compass has assembled a highly experienced commercial leadership team and is advancing comprehensive launch preparedness efforts, including education initiatives with key opinion leaders and healthcare providers, ensuring that COMP360 can successfully meet market demands upon launch.
See More
